Literature DB >> 30508148

CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease.

Kaiwen Wang1, Jiangfeng Zhao1, Zhiwei Chen1, Ting Li1, Xiaoming Tan2, Yu Zheng2, Liyang Gu1, Li Guo1, Fangfang Sun1, Haiting Wang1, Jiajie Li1, Xiaodong Wang1, Gabriela Riemekasten3, Shuang Ye1.   

Abstract

BACKGROUD: There is an unmet need for the development of new biomarkers for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD).
METHODS: Peripheral CD4+CXCR4+ T cells, stromal cell-derived factor-1 and Krebs von den Lungen-6 were measured in patients with IIM-ILD (n = 85) and controls. The relation to pulmonary functions, high-resolution CT scores, specific clinical phenotypes and survival was analysed. Cytokine-expression profiling of these CD4+CXCR4+ T cells and their co-culture with pulmonary fibroblasts were conducted.
RESULTS: The peripheral percentages of CD4+CXCR4+ T cells were significantly elevated in IIM-ILD patients, and correlated with high-resolution CT score (r = 0.7136, P < 0.0001) and pulmonary function impairments, such as percentage of forced volume vital capacity (r = -0.4734, P = 0.0005). They were associated with anti-melanoma differentiation-associated gene 5 autoantibodies and the amyopathic DM phenotype. In IIM-ILD, peripheral percentages of CD4+CXCR4+ T cells ⩾30% revealed a 6-month mortality as high as 47%. These CD4+CXCR4+ T cells express high levels of IL-21 and IL-6. In vitro blockade of IL-21 signalling by neutralization of IL-21 or Janus kinase inhibitor could abolished the fibroblast proliferation.
CONCLUSION: Overall, peripheral CD4+CXCR4+ T cells appear to be a potentially valuable novel biomarker associated with the severity and prognosis of IIM-ILD. They promote pulmonary fibroblast proliferation via IL-21, which may herald future targeted treatments for this severe disease.
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CD4+CXCR4+; T cells; amyopathic dermatomyositis; idiopathic inflammatory myopathy; interleukin 21; interstitial lung disease

Mesh:

Substances:

Year:  2019        PMID: 30508148     DOI: 10.1093/rheumatology/key341

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.

Authors:  Erin M Wilfong; Todd Bartkowiak; Katherine N Vowell; Camille S Westlake; Jonathan M Irish; Peggy L Kendall; Leslie J Crofford; Rachel H Bonami
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 8.786

2.  Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.

Authors:  Walter Conca; Ihab Weheba; Mohei-Eldin Abouzied; Abeer Abdelsayed; Yousif Aleyouni; Eid Al-Mutairy; Nasir Bakshi; Mohammad Khalid
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

3.  Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Lin Liang; Ya-Mei Zhang; Ya-Wen Shen; Ai-Ping Song; Wen-Li Li; Li-Fang Ye; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Front Cell Dev Biol       Date:  2021-03-25

Review 4.  Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon System.

Authors:  Huifang Hu; Hang Yang; Yi Liu; Bing Yan
Journal:  Front Med (Lausanne)       Date:  2022-01-24

5.  A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis.

Authors:  Wenwen Xu; Wanlong Wu; Yu Zheng; Zhiwei Chen; Xinwei Tao; Danting Zhang; Jiangfeng Zhao; Kaiwen Wang; Bingpeng Guo; Qun Luo; Qian Han; Yan Zhou; Shuang Ye
Journal:  Front Med (Lausanne)       Date:  2021-11-29

6.  AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases.

Authors:  Renjiao Li; Wen-Jun Zhu; Faping Wang; Xiaoju Tang; Fengming Luo
Journal:  Arthritis Res Ther       Date:  2020-09-20       Impact factor: 5.156

7.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

8.  Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.

Authors:  Chenjia He; Wenyu Li; Qibing Xie; Geng Yin
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

9.  Low Circulating Monocytes Is in Parallel With Lymphopenia Which Predicts Poor Outcome in Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Xia Lv; Yuyang Jin; Danting Zhang; Yixuan Li; Yakai Fu; Suli Wang; Yan Ye; Wanlong Wu; Shuang Ye; Bing Yan; Xiaoxiang Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-17

10.  Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.

Authors:  Yuichi Ishikawa; Tadamichi Kasuya; Michio Fujiwara; Yasuhiko Kita
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.